Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lixte Biotechnology HoldingsLIXTW +4.74%34 EBITDA Margin % is 0.00% as of Jun. 2026. GuruFocus rates LIXTW with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 3,047 Industrial Products companies, Lixte Biotechnology Holdings ranks worse than 32819.13% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Lixte Biotechnology Holdings EBITDA Margin % Related Terms
Lixte Biotechnology Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LIXTW vs CBAT, TGEN, STI: EBITDA Margin % Comparison
For the Electrical Equipment & Parts subindustry, Lixte Biotechnology Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lixte Biotechnology Holdings EBITDA Margin % vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Lixte Biotechnology Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Lixte Biotechnology Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lixte Biotechnology Holdings (LIXTW) has a EBITDA Margin % of 0.00% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lixte Biotechnology Holdings and its competitors. According to the industry distribution chart, Lixte Biotechnology Holdings ranks #999999 out of 3047 companies in the Industrial Products industry.
Is Lixte Biotechnology Holdings' EBITDA Margin % too high?
Lixte Biotechnology Holdings' current EBITDA Margin % is 0.00%. Based on the distribution chart, Lixte Biotechnology Holdings ranks #999999 out of 3047 companies in the Industrial Products industry, which is in the bottom quartile relative to peers. Overall, Lixte Biotechnology Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Lixte Biotechnology Holdings' EBITDA Margin % compare to CBAT and TGEN?
According to the Industrial Products industry distribution chart, Lixte Biotechnology Holdings ranks #999999 out of 3047 companies for EBITDA Margin %. This places Lixte Biotechnology Holdings in the lower half of its industry. The industry median EBITDA Margin % is 9.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for an Industrial Products company?
The median EBITDA Margin % among Industrial Products companies is 9.39, based on 3,047 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lixte Biotechnology Holdings and its competitors. For the Industrial Products industry, the median EBITDA Margin % is 9.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lixte Biotechnology Holdings's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lixte Biotechnology Holdings stock overvalued right now?
Lixte Biotechnology Holdings (LIXTW) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Lixte Biotechnology Holdings' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Lixte Biotechnology Holdings (LIXTW), the current EBITDA Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
34GF Score
Get the complete analysis for LIXTW
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIXTW has been successfully added to your 
